Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421468 | 0.83 | AR (0.50) | ARPGR | |
| SCHEMBL325632 | 0.83 | AR (0.50) | ARPGR | |
| SCHEMBL5175526 | 0.83 | AR (0.48) | ARPGR | |
| SCHEMBL17588986 | 0.82 | AR (0.45) | ARPGR | |
| SCHEMBL21332929 | 0.81 | AR (0.75) | AR | |
| SCHEMBL5174403 | 0.81 | AR (0.53) | ARPGR | |
| SCHEMBL5711220 | 0.81 | AR (0.72) | ARPGR | |
| SCHEMBL29891719 | 0.79 | AR (0.43) | ARPGR | |
| SCHEMBL6211022 | 0.79 | AR (0.43) | ARPGR | |
| SCHEMBL1003776 | 0.79 | AR (0.58) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 774 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798228-A | PROTAC compound for targeted degradation of AR/AR-V7 and preparation method and application thereof | 常州大学 | 2025-04-11 | — | — | CN | claimed |
| CN-118315670-A | Electrolyte additive and application thereof, single-particle graphite negative electrode electrolyte and application thereof | 国网湖南省电力有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-113527130-B | Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound | 兰州大学 | 2023-07-18 | — | — | CN | claimed |
| CN-113527130-A | Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound | 兰州大学 | 2021-10-22 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-101759597-B | Preparation method of 2-trifluoromethyl-4-aminobenzonitrile | SHANGHAI CHEMSPEC INTERNAT LTD | 2013-09-04 | — | — | CN | claimed |
| CN-1810775-B | Preparation process of 4-amino-2-trifluoromethyl benzonitrile | BAOQING TANG | 2012-05-09 | — | — | CN | claimed |
| CN-101759597-A | Preparation method of 2-trifluoromethyl-4-aminobenzonitrile | CHEMSPEC INTERNAT LTD | 2010-06-30 | — | — | CN | claimed |
| CN-1810775-A | Novel method for preparing 4-amino-2-trifluoromethyl benzonitrile | TANG BAOQING (CN) | 2006-08-02 | — | — | CN | claimed |
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025217141-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 | ENANTA PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2002024638-A1 | PROCESS FOR THE PREPARATION OF N-(SUBSTITUTED PHENYL)-3-ALKYL-, ARYL- AND HETEROARYLSULFONYL-2-HYDROXY-2-ALKYL- AND HALOALKYLPROPANAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
| JP-2001097937-A | METHOD FOR PRODUCING 4-FLUORO-2- TRIFLUOROMETHYLBENZONITRILE | CENTRAL GLASS CO LTD | 2001-04-10 | — | — | JP | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | AR 2064/4885PGR 3642/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | AR 1556/4885PGR 2047/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | AR 438/4885PGR 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.